Application of tanshinone I to treatment of microglia-mediated disease

A technology of microglia and tanshinone, applied in the field of tanshinone I, can solve the problems of decreased curative effect, toxic and side effects, etc.

Inactive Publication Date: 2012-07-11
TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are problems such as obvious toxic and side effects in clinical trea

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tanshinone I to treatment of microglia-mediated disease
  • Application of tanshinone I to treatment of microglia-mediated disease
  • Application of tanshinone I to treatment of microglia-mediated disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Example 1: Effect of Tanshinone I on Microglia Activation-Induced Cell Death (AICD)

[0065] BV-2 cells were pre-incubated with tanshinone I (1, 5, 10, 20 μmol / L) for 0.5 h, and then stimulated with LPS (lipopolysaccharide, 0.1 μg / mL). After culturing for 24 hours, discard the supernatant, add CCK-8 (cell counting reagent, Guangzhou Yanchuang Biotechnology Co., Ltd.), continue to incubate for 30 minutes, and measure the absorbance at a wavelength of 450 nm. The experiment also set up the control group (normally growing cells), the model group (LPS) and the positive control group "Mino+LPS" group (5 μmol / L minocycline+lipopolysaccharide) in parallel. see results figure 1 .

[0066] The results showed that LPS can cause activation-induced cell death and significantly reduce the viability of BV-2 cells. Tanshinone I can inhibit LPS-induced activation-induced cell death in a dose-dependent manner.

[0067] In addition, "extract A" and "extract B" were tested as reagen...

Embodiment 2

[0068] Example 2: Effect of Tanshinone I on Viability of Microglial Cells

[0069] After BV-2 cells were cultured with tanshinone I (1, 5, 10, 20 μmol / L) for 24 hours, discard the supernatant, add CCK-8, continue to incubate for 30 minutes, and measure the absorbance at a wavelength of 450 nm. In the experiment, the control group (cells with normal growth) and the "Mino" group were set up in parallel. see results figure 2 .

[0070] The results showed that tanshinone I could not inhibit cell viability and did not cause cell death.

Embodiment 3

[0071] Example 3: Effect of Tanshinone I on Secretion of Inflammatory Mediators by Microglia

[0072] The mouse microglial cell line BV-2 was cultured in complete DMEM medium. Inoculate into 48-well culture plate overnight, add different concentrations of Tanshinone I (final concentration 1, 5, 10, 20 μmol / L) for pre-incubation for 0.5 h, and then add endotoxin (LPS, final concentration 0.1 μg / mL) for stimulation . Experimental groups: normal control group, LPS group, Tanshinone I plus LPS group, and "Mino+LPS" group. The concentration of NO was detected by Greiss method, and the concentration of TNF-α was measured by Elisa kit. see results image 3 .

[0073] The results showed that Tanshinone I could significantly inhibit the release of NO and TNF-α induced by LPS in a dose-dependent manner within the concentration range of 1-20 μmol / L.

[0074] In addition, "extract A" and "extract B" were tested as reagents, and the two extracts showed the same dose as the pure tans...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of tanshinone I shown in a formula I to the treatment of a microglia-mediated disease, in particular to an application of tanshinone I to the preparation of a medicament for treating and/or preventing the microglia-mediated disease, in particular to an application of tanshinone I to preparation of a medicament for treating and/or preventing psychoneuroimmunology chronic inflammatory diseases caused by microglia-mediated neurotoxic effects. The tanshinone I provided by the invention has the novel functions of remarkably suppressing microglia cell-activated and induced cell death, suppressing the generation and expression of inflammatory mediators, i.e., NO and TNF alpha of microglia cells, and remarkably lowering the cell toxicity of activated microglia cells on neurons, the tanshinone I can be applied to prevention and treatment of brain immune inflammation-related diseases such as Alzheimer's disease, Parkinson's disease, and the like. The formula I is shown in the specifications.

Description

technical field [0001] The present invention relates to a new application of tanshinone I, in particular to the treatment and / or prevention of tanshinone I mediated neuroimmune inflammation-related diseases, such as Alzheimer's disease, Parkinson's disease, traumatic brain injury, encephalitis , multiple sclerosis and other diseases. Background technique [0002] Salvia miltiorrhiza is the dried root and rhizome of salvia miltiorrhiza Bge., a plant in the Labiatae family, and is a commonly used traditional Chinese medicine in my country. Modern research shows that the chemical composition of Salvia miltiorrhiza is mainly divided into two parts: water-soluble and fat-soluble. The water-soluble components mainly include salvianolic acid A, salvianolic acid B, etc. The fat-soluble components mainly include tanshinone II A and II B, as well as tanshinone I, cryptotanshinone, hydroxytanshinone, hydroxy tanshinone, etc. (Chinese Wild Plant Resources, 2003, 22(6): 1-4). It has b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/343A61K36/537A61K36/344A61P25/00A61P37/02A61P29/00A61P25/28A61P25/16A61P25/14A61K125/00
Inventor 王少峡胡利民高秀梅王虹康立源
Owner TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap